Pharmacological evidence for the 5-HT7 receptor mediating smooth muscle relaxation in canine cerebral arteries

British Journal of Pharmacology

Volumn 127, Issue 3, 1999, Pages 609-616

  Terrón, José A ^a,b   Falcón Neri, Alicia ^a  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

5 HT7 receptor; 5 Hydroxytryptamine; Basilar artery; Middle cerebral artery; Migraine; Relaxation; Vascular smooth muscle

Indexed keywords

5 CARBAMOYLTRYPTAMINE; 5 METHOXYTRYPTAMINE; ALPHA METHYLSEROTONIN; CLOZAPINE; KETANSERIN; MESULERGINE; METITEPINE; N (2 HYDROXYCYCLOPENTYL) 1 ISOPROPYL 6 METHYLERGOLINE 8 CARBOXAMIDE; N [4 METHOXY 3 (4 METHYL 1 PIPERAZINYL)PHENYL] 2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL)[1,1' BIPHENYL] 4 CARBOXAMIDE; PROSTAGLANDIN F2 ALPHA; RISPERIDONE; SEROTONIN; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 7 RECEPTOR; SPIPERONE; SUMATRIPTAN; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTERY CONSTRICTION; ARTERY MUSCLE; ARTICLE; BASILAR ARTERY; BINDING AFFINITY; BRAIN ARTERY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOG; DRUG POTENCY; FEMALE; MALE; MIDDLE CEREBRAL ARTERY; MIGRAINE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; SMOOTH MUSCLE RELAXATION; SMOOTH MUSCLE TONE; VASCULAR ENDOTHELIUM;

ANIMALS; BASILAR ARTERY; CEREBRAL ARTERIES; DINOPROST; DOGS; ENDOTHELIUM, VASCULAR; FEMALE; MALE; MUSCLE RELAXATION; MUSCLE, SMOOTH, VASCULAR; RECEPTORS, SEROTONIN; SEROTONIN; SEROTONIN AGONISTS; SPIPERONE; SUMATRIPTAN;

EID: 0032993173     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0702580     Document Type: Article

References (55)

1. Allen, G.S., Henderson, M.L., Chou, S.N. & French, L.A. (1974). Cerebral arterial spasm Part 1: In vitro contractile activity of vasoactive agents on canine basilar and middle cerebral arteries. J. Neurosurg., 40, 433-441.
2. Arunlakshana, O. & Shild, H.D. (1959). Some quantitative uses of drugs antagonists. Br. J. Pharmacol., 14, 48-58.
3. 7) positively linked to adenylate cyclase. J. Biol. Chem., 268, 23422-23426.
4. 2 receptor subtypes: a family re-united? Trends Pharmacol. Sci., 16, 105-110.
5. Bodelsson, M., Tornebrandt, K. & Arneklo-Nobin, B. (1993). Endothelial relaxing 5-hydroxytryptamine receptors in the rat jugular vein; similarity with the 5-hydroxytryptamine1C receptor. J. Pharmacol. Exp. Ther., 264, 709-716.
6. Connor, H.E. & Feniuk, W. (1989). Influence of the endothelium on contractile effects of 5-hydroxytryptamine and selective 5-HT agonists in canine basilar artery. Br. J. Pharmacol., 96, 170-178.
7. 1-like receptor agonist. Br. J. Pharmacol., 96, 379-387.
8. 7 receptor ligand, blocks serotonin-induced relaxation in canine coronary artery. J. Pharmacol. Exp. Ther., 277, 1560-1566.
9. 7 receptor: orphan found. Trend Pharmacol. Sci., 18, 104-107.
10. Edvinsson, L., Hardebo, J.E. & Owman, C. (1978). Pharmacological analysis of 5-hydroxytryptamine receptors in isolated intracranial vessels of cat and man. Circ. Res., 42, 143-151.
11. Fozard, J.R. (1982). Serotonin, migraine and platelets: In Drugs and platelets. eds. Van Zwieten, P.A. & Schönbaum, E. pp. 135 146. New York: Gustav Fischer Verlag.
12. 1C receptor agonism as an initiating event in migraine. In 5-Hydroxytryptamine mechanisms in primary headache. eds. Olesen, J. & Saxena, P.R. pp. 200-212. New York: Raven Press.
13. Fozard, J.R. (1995). The 5-hydroxytryptamine-nitric oxide connection: the key link in the initiation of migraine? Arch. Int. Pharmacodyn. Ther., 329, 111-119.
14. Fozard, J.R. & Kalkman, H.O. (1994). 5-Hydroxytryptamine (5-HT) and the initiation of migraine: new perspectives. Naunyn-Schmiedeberg's Arch. Pharmacol., 350, 225-229.
15. Friberg, L., Olesen, J., Iversen, H.K. & Sperling, B. (1991). Migraine pain associated with middle cerebral artery dilatation: reversal by sumatriptan. Lancet, 338, 13-17.
16. Glusa, E. & Richter, M. (1993). Endothelium-dependent relaxation of porcine pulmonary arteries via 5-HT1C-like receptors. Naunyn-Schmiedeberg's Arch. Pharmacol., 347, 471-477.
17. Hoyer, D., Clarke, D.E., Fozard, J.R., Hartig, P.R., Martin, G.R., Mylecharane, E.J., Saxena, P.R. & Humphrey, P.P.A. (1994). International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol. Rev., 46, 157-203.
18. Humphrey, P.P.A. & Feniuk, W. (1991). Mode of action of the anti-migraine drug sumatriptan. Trends Pharmacol. Sci., 12, 444-446.
19. Kimball, R.W., Friedman, A.P. & Vallejo, E. (1960). Effect of serotonin in migraine patients. Neurology (Minneap.), 10, 107-111.
20. Leff, P., Martin, G.R. & Morse, J.M. (1987). Differential classification of vascular smooth muscle and endothelial cell 5-HT receptors by use of tryptamine analogues. Br. J. Pharmacol., 91, 321-331.
21. Leung, E., Walsh, L.K., Pulido-Rios, M.T. & Eglen, R.M. (1996). Characterization of putative 5-ht7 receptors mediating direct relaxation in Cynomolgus monkey isolated jugular vein. Br. J. Pharmacol., 117, 926-930.
22. 7) implicated in the regulation of mammalian circadian rhythms. Neuron, 11, 449-458.
23. Martin, G.R., Leff, P., Cambridge, D. & Barret, V.J. (1987). Comparative analysis of two types of 5-hydroxytryptamine receptor mediating vasorelaxation: differential classification using tryptamines. Naunyn-Schmiedeberg's Arch. Pharmacol., 336, 365-373.
24. 7 receptor? Br. J. Pharmacal., 114, 383P.
25. Moskowitz, M.A. (1992). Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol. Sci., 13, 307-311.
26. O'Brien, M.D. (1971). Cerebral blood flow changes in the migraine headache. Headache, 10, 139-143.
27. Olesen, J., Thomsen, L.L. & Iversen, H. (1994). Nitric oxide is a key molecule in migraine and other vascular headaches. Trends Pharmacol. Sci., 15, 149-153.
28. Ostfeld, A.M. & Wolff, H.G. (1958). Identification mechanisms and managements of the migraine syndrome. Med. Clin. N. Amer., 42, 1497-1509.
29. Plassat, J.L., Amlaiky, N. & Hen, R. (1993). Molecular cloning of a mammalian serolonin receptor that activates adenylate cyclase. Mol. Pharmacol., 44, 229-236.
30. 7) activating cAMP formation. Proc. Natl. Acad. Sci. U.S.A., 90, 8547-8551.
31. Saxena, P.R. (1972). The effects of antimigraine drugs on the vascular responses by 5-hydroxytryptamine and related biogenic substances on the external carotid bed of dogs: Possible pharmacological implications to their antimigraine action. Headache, 12, 44-53.
32. Saxena, P.R. & De Vlaam-Schluter, G.M. (1974). Role of some biogenic substances in migraine and relevant mechanism in antimigraine action of ergotamine Studies in an experimental model for migraine. Headache, 13, 142-163.
33. 1-like receptor agonists and the pathophysiology of migraine. Trends Pharmacol. Sci., 10, 200-204.
34. 2B receptors: An early step in the generation of migraine headache? Eur. J. Neurosci., 8, 959-967.
35. 7 serotonin receptor subtype. J. Biol. Chem., 268, 18200-18204.
36. Sicuteri, F., Testi, A. & Anselmi, B. (1961). Biochemical investigations in headache: increase in the hydroxyindolcacetic acid excretion during migraine attacks. Int. Arch. Allergy, 19, 55-58.
37. Silberstein, S.D. (1994). Serotonin (5-HT) and migraine. Headache, 34, 408-417.
38. Sjaastad, O. (1975). The significance of blood serotonin levels in migraine. A critical review. Acta Neurol. Scand., 51, 200-210.
39. 1D receptor antagonist. Behav. Brain Res., 73, 157-161.
40. Skinhöj, E. & Paulson, O.B. (1969). Regional blood flow in internal carotid distribution during migraine attack. Br. Med. J., 3, 569-570.
41. Sumner, M.J. (1991). Characterization of the 5-HT receptor mediating endothelium-dependent relaxation in porcine vena cava. Br. J. Pharmacol., 97, 292-300.
42. Sumner, M.J., Feniuk, W. & Humphrey, P.P.A. (1989). Further characterization of the 5-HT receptor mediating vascular relaxation and elevation of cyclic AMP in porcine isolated vena cava. Br. J. Pharmacol., 97, 292-300.
43. 7 receptor subtype. Br. J. Pharmacol., 118, 1421-1428.
44. 1 receptor mediating direct relaxation to 5-hydroxytryptamine in canine cerebral blood vessels. Ann. N.Y. Acad. Sci., 861, 283.
45. 7 receptors in the long-lasting hypotensive response induced by 5-hydroxytryptamine in the rat. Br. J. Pharmacol., 121, 563-571.
46. 7 receptor: a target for novel therapeutic avenues? I. Drugs, 1, 302-310.
47. 7 receptor ligand, LY215840. Proc. West. Pharmacol. Soc., 41, 129-130.
48. 7 receptor in cerebrovascular vasodilation: potential impact in migraine. Proc. West. Pharmacol. Soc., 41, 247-251.
49. Trevethick, M.A., Feniuk, W. & Humphrey, P.P.A. (1986). 5-Carboxamidotryptamine: a potent agonist mediating relaxation and elevation of cyclic AMP in the isolated neonatal porcine vena cava, Life Sci., 38, 1521-1528.
50. Tunis, M.M. & Wolff, H.G. (1952). Analysis of cranial artery pulse waves in patients with vascular headaches of migraine type. Amer. J. Med. Sci., 224, 565-568.
51. 1-like receptor subtype mediates cAMP synthesis in porcine pial vein. Am. J. Physiol., 268, H1383-H1389.
52. Ullmer, C., Schmuck, K., Kalkman, H.O. & Lubert, H. (1995). Expression of serotonin receptor mRNAs in blood vessels. FEBS Lett., 370, 215-221.
53. Van Haastert, P.J., Van Driel, R., Jastorff, B., Baraniak, J., Stec, W.J. & De Wit, R.J. (1984). Competitive cAMP antagonists for cAMP-receptor proteins. J. Biol. Chem., 259, 10020-10024.
54. Verrechia, C., Sercombe, R., Philipson, V. & Seylaz, J. (1986). Functional destruction of cerebral vascular endothelium by Triton X-100. Blood Vessels, 23, 106.
55. 7 receptor. Br. J. Pharmacol., 120, 1319-1327.